文献速递免疫规划传染病防控与疫情报告

朝觐成人中Tdap与MCV4-CRM197不同顺序接种对W群脑膜炎球菌免疫原性的影响

Effect on meningococcal serogroup W immunogenicity when Tdap was administered prior, concurrent or subsequent to the quadrivalent (ACWY) meningococcal CRM197-conjugate vaccine in adult Hajj pilgrims: A randomised controlled trial.
PubMed 文献 · Vaccine · 2019-05-23

结果显示各组接种MCV4-CRM197后W群rSBA GMT无显著差异(A=404,B=984,C=1235,p=0.15),达到≥4倍升高或rSBA≥8的比例亦无统计学差异,提示同时接种具有免疫原性且切实可行。

要点

  • Tdap与MCV4-CRM197先后或同时接种,W群rSBA GMT无显著差异。
  • 各组达到≥4倍rSBA升高或rSBA≥8的比例无统计学差异。
  • 同时接种MCV4-CRM197与Tdap具有免疫原性且操作可行。

核心结论

  • MCV4-CRM197在Tdap之前、同时或之后接种对W群脑膜炎球菌的免疫反应相似,同时接种兼具免疫原性与可行性。

研究设计与样本

  • A组先接种Tdap,3–4周后接种MCV4-CRM197(含PCV13);B组同次就诊接种三种疫苗;C组先接种MCV4-CRM197(含PCV13),3–4周后接种Tdap。

主要发现

  • 接种MCV4-CRM197后W群rSBA GMT分别为A组404、B组984、C组1235,组间无显著差异(p=0.15)。
  • 各组达到rSBA≥4倍升高或rSBA滴度≥8的比例无统计学差异。

临床怎么用

  • 朝觐等需多种疫苗接种的旅行者可采用MCV4-CRM197与Tdap同时接种,不显著影响W群免疫应答。

局限性

  • 原文建议进一步研究载体诱导的免疫抑制是否构成公共卫生问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune responses to the capsular polysaccharide administered in the polysaccharide-protein conjugate vaccines can be either improved or suppressed by the pre-existence of immunity to the carrier protein. Receiving multiple vaccinations is essential for travellers such as Hajj pilgrims, and the use of conjugated vaccines is recommended. We studied the immune response to meningococcal serogroup W upon prior, concurrent and sequential administration of a quadrivalent meningococcal conjugate vaccine (MCV4) conjugated to CRM197 (coadministered with 13 valent pneumococcal vaccine conjugate CRM197 [PCV13]), and tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Australian adults before attending the Hajj pilgrimage in 2014. Participants were randomly assigned, by computer-generated numbers, to three study arms by 1:1:1 ratio. Group A received Tdap followed by MCV4-CRM197 (+PCV13) 3-4 weeks later. Group B received all three vaccines in a single visit. Group C received MCV4-CRM197 (+PCV13) followed by Tdap 3-4 weeks later. Blood samples obtained prior to and 3-4 weeks after immunisation with MCV4-CRM197 were tested for meningococcal serogroup W-specific serum bactericidal antibody responses using baby rabbit complement (rSBA). One hundred and seven participants aged between 18 and 64 (median 40) years completed the study. No significant difference in meningococcal serogroup W rSBA geometric mean titre (GMT) was observed between the study arms post vaccination with MCV-CRM197 but Group A tended to have a slightly lower GMT (A = 404, B = 984 and C = 1235, p = 0.15). No statistical difference was noticed between the groups in proportions of subjects achieving a ≥4-fold rise in rSBA titres or achieving rSBA titre ≥8 post vaccination. In conclusion, receipt of MCV4-CRM197 vaccine prior, concurrent or subsequent to Tdap has similar immunologic response, and hence concurrent administration is both immunogenic and practical. However, further investigation into whether carrier induced suppression is a public health issue is suggested. Clinical trial registration: ANZCTR no. ACTRN12613000536763.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tashani M, Badahdah AM, Alfelali M, et al. Effect on meningococcal serogroup W immunogenicity when Tdap was administered prior, concurrent or subsequent to the quadrivalent (ACWY) meningococcal CRM197-conjugate vaccine in adult Hajj pilgrims: A randomised controlled trial. Vaccine. 2019. PMID: 31128875. doi:10.1016/j.vaccine.2019.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。